GlassScriptPhysician profile
Rizwan Aslam
NPI 1174885750
$2,008.49
in general payments reported to CMS, 2019-2025
22 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $154 · 2021: $252 · 2022: $256 · 2023: $423 · 2024: $428 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.99 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $464.69 | 2020-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $346.01 | 2019-2025 | Jynarque |
| Outset Medical INC | $144.92 | 2022-2023 | |
| Glaxosmithkline, LLC. | $137.08 | 2022-2024 | Benlysta |
| Novo Nordisk INC | $125.09 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Vifor Pharma, INC. | $123.26 | 2020-2023 | Korsuva, Veltassa |
| Novartis Pharmaceuticals Corporation | $108.50 | 2025 | |
| Aurinia Pharma U.S., INC. | $95.32 | 2021 | |
| Ardelyx, INC. | $82.71 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.65 | 2025 | Jardiance |
| Amgen INC. | $57.83 | 2022-2024 | Krystexxa |
| Travere Therapeutics, INC. | $50.50 | 2022-2024 | |
| Baxter Healthcare | $43.78 | 2023 | |
| Scpharmaceuticals INC. | $30.35 | 2025 | |
| Calliditas Therapeutics US INC. | $24.46 | 2023 | Tarpeyo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $19.94 | 2025 | Monoferric |
| Akebia Therapeutics INC | $18.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.67 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.02 | 2023 | |
| Horizon Therapeutics Plc | $15.97 | 2022 | |
| Opko Pharmaceuticals, LLC | $14.93 | 2024 | Rayaldee |
| Amag Pharmaceuticals, INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.